Crispr Therapeutics names internal veteran Andrew Silver as CFO
Crispr Therapeutics appointed Andrew Silver chief financial officer, replacing Raju Prasad, who is leaving the biopharma company to pursue external opportunities.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Crispr Therapeutics has promoted Senior Vice President of Finance Andrew Silver to chief financial officer, effective Monday. He replaces Raju Prasad, who is stepping down to pursue external opportunities, the company said. According to Dow Jones Newswires, Silver has held the CFO role since January 2025.
Silver joined Crispr in October 2018 and has worked across strategic finance, treasury, planning, accounting, tax and financial operations. Before that he spent more than ten years at Ernst & Young and became a certified public accountant. A filing with the SEC shows an annual salary of $515,000, a target bonus of 45% of base salary, and a one-time grant of 25,000 restricted stock units.
why it matters
A CFO change draws investor attention to management stability, but for the broader market the appointment carries little weight. For Crispr shareholders, the compensation details disclosed in the regulatory filing are the main takeaway.
tags
instruments
sources
- Crispr Therapeutics Promotes Andrew Silver to CFO — Dow Jones Newswires, 19 October 2026 at 21:25 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗